GNPX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GNPX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Genprex's interest expense for the three months ended in Dec. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Genprex's Operating Income for the three months ended in Dec. 2023 was $ -5.99 Mil. Genprex's Interest Expense for the three months ended in Dec. 2023 was $ 0.00 Mil. Genprex has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical data trend for Genprex's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genprex Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Interest Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Genprex Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Interest Expense | Get a 7-Day Free Trial | - | - | - | - | - |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genprex (NAS:GNPX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Genprex's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-5.99 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.00 Mil.
Genprex's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
Genprex had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Genprex Inc has no debt.
Catherine M Vaczy | officer: EVP & Chief Strategy Officer | C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747 |
John Rodney Varner | director, 10 percent owner, officer: Chief Executive Officer | P.O. BOX 162341, AUSTIN TX 78716 |
Hermant Kumar | officer: Chief Mfgr & Tech Officer | 3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746 |
Mark Stanley Berger | officer: Chief Medical Officer | 140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024 |
Brent M Longnecker | director | C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626 |
Moreno Toscano Jose Antonio | director | 1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732 |
Wilson William R Jr. | director | 1407 ETHRIDGE AVE, AUSTIN TX 78703 |
Michael Thomas Redman | officer: EVP & Chief Operating Officer | 16402 EMILIA COURT, SPRING TX 77379 |
John N Bonfiglio | director | C/O MICROLIN BIO, INC., NEW YORK NY 10022 |
Genprex, Inc. | director, 10 percent owner, officer: Chief Executive Officer | 1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712 |
Julien L Pham | officer: Chief Operating Officer | 944 DORCHESTER AVE #56, BOSTON MA 02125 |
Jack A Roth | 10 percent owner | 6516 BROMPTON ROAD, HOUSTON TX 770055 |
Christy M. Nance | 10 percent owner | 8305 SCENIC RIDGE COVE, AUSTIN TX 78735 |
Ryan M. Confer | officer: Chief Financial Officer | 1000 SAN MARCOS ST. #460, AUSTIN TX 78702 |
Robert W. Pearson | director | 3001 MEANDERING RIVER COURT, AUSTIN TX 78746 |
From GuruFocus
By PRNewswire PRNewswire • 12-14-2022
By Marketwired • 09-21-2023
By PRNewswire PRNewswire • 12-02-2022
By PRNewswire PRNewswire • 05-30-2023
By PRNewswire PRNewswire • 04-18-2023
By PRNewswire • 08-22-2023
By PRNewswire • 11-01-2023
By PRNewswire PRNewswire • 08-16-2022
By PRNewswire PRNewswire • 05-25-2023
By PRNewswire • 07-18-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.